ECOR1 CAPITAL LLC
Q1 2025 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001587114 · CRD 167121 · SEC-registered investment adviser
$1.7B Reported Value Total

ECOR1 CAPITAL, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $3,914,180,012, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
5 funds · $3.4B gross asset value
Hedge Fund: $3.4B · Venture Capital Fund: $65.4M
Source: Form ADV filed 2026-03-30
Reported value
$1.7B
Quarter over quarter
-26.1%
Holdings
44
Top-10 concentration
80.0%

Filing Structure

Reports holdings for

  • NODELMAN OLEG (not a 13F filer in our records) · File #028-16767 · Q4 2014 – Q4 2014

Key People

Form ADV owners & control persons
Sarah Christine Marriott
MEMBER, CCO, COO
Oleg Nmn Nodelman
MANAGER
Scott Eric Perlen
CFO

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2025 13F record

Q1 2025 13F filing summary

Q1 2025 Form 13F portfolio summary
Period of report March 31, 2025
Filed May 15, 2025
Form 13F-HR
Reported value $1.7B
Positions 44
Change in reported value -36.3%
New positions 5
Exited positions 16
Position turnover 35.0%
Top-10 concentration 80.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
34 $2.3B
Q2 2026 13F
Filed Aug 14, 2026
31 $2.1B
Q1 2026 13F
Filed May 15, 2026
29 $2.4B
Q4 2025 13F
Filed Feb 17, 2026
28 $2.2B
Q3 2025 13F
Filed Nov 14, 2025
30 $2.1B
Q2 2025 13F
Filed Aug 14, 2025
36 $1.7B
Q1 2025 13F
Filed May 15, 2025
44 $1.7B
Q4 2024 13F
Filed Feb 14, 2025
55 $2.6B
Q3 2024 13F
Filed Nov 14, 2024
63 $2.9B
Q2 2024 13F
Filed Aug 14, 2024
55 $3.3B
Q1 2024 13F
Filed May 15, 2024
57 $4.0B
Q4 2023 13F
Filed Feb 14, 2024
51 $3.9B
Q3 2023 13F
Filed Nov 14, 2023
49 $3.0B
Q2 2023 13F
Filed Aug 14, 2023
51 $4.1B
Q1 2023 13F
Filed May 15, 2023
58 $3.1B
Q4 2022 13F
Filed Feb 14, 2023
66 $3.3B
Q3 2022 13F
Filed Nov 14, 2022
75 $3.4B
Q2 2022 13F
Filed Aug 15, 2022
78 $2.9B
Q1 2022 13F
Filed May 16, 2022
86 $3.2B
Q4 2021 13F
Filed Feb 14, 2022
75 $3.1B

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2025

Largest Q1 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 APLS APELLIS PHARMACEUTICALS INC $260.2M 15.43%
2 JAZZ JAZZ PHARMACEUTICALS PLC $211.9M 12.57%
3 ZYME ZYMEWORKS INC $205.6M 12.19%
4 ANAB ANAPTYSBIO INC $146.5M 8.69%
5 CRNX CRINETICS PHARMACEUTICALS IN $143.8M 8.53%
6 PRTA PROTHENA CORP PLC $143.4M 8.5%
7 SRPT SAREPTA THERAPEUTICS INC $82.5M 4.89%
8 XNCR XENCOR INC $65.4M 3.88%
9 CRSP CRISPR THERAPEUTICS AG $47.3M 2.8%
10 QURE UNIQURE NV $42.3M 2.51%
11 JANX JANUX THERAPEUTICS INC $39.7M 2.35%
12 IMNM IMMUNOME INC $27.5M 1.63%
13 ETON ETON PHARMACEUTICALS INC $25.2M 1.49%
14 MDGL MADRIGAL PHARMACEUTICALS INC $24.8M 1.47%
15 ORIC ORIC PHARMACEUTICALS INC $19.1M 1.13%
16 AKRO AKERO THERAPEUTICS INC $17.8M 1.06%
17 KURA KURA ONCOLOGY INC $17.4M 1.03%
18 TECX TECTONIC THERAPEUTIC INC $16.6M 0.98%
19 RNA AVIDITY BIOSCIENCES INC $16.5M 0.98%
20 NGNE NEUROGENE INC $14.9M 0.88%

Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings